Sarepta bags drug to fully unlock DMD gene therapy opportunity MEI Pharma, Helsinn Group cut losses, ditch phase 3 partnered cancer test for pracinostat Pfizer-backed Bolt Therapeutics strikes $93.5M funding round as lead med hits the clinic British cell therapy biotech Rexgenero nabs life science veteran as CMO Annexon grabs $100M from a host of top VC firms for complement therapies 5 FDA-approved antivirals could target COVID-19: study FiercePharmaAsia—GSK's, Akebia's anemia nods; Takeda's Xiidra loss and $900M gene therapy deal Chutes & Ladders—Novavax taps Machielse to head manufacturing in lead up to approvals Featured Story | By Nick Paul Taylor Sarepta Therapeutics has secured a license to a drug that could enable more patients to receive its gene therapies. The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in Duchenne muscular dystrophy and limb-girdle muscular dystrophy patients. read more |
| |
|---|
|
Top Stories By Ben Adams Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016, but now the pair is closing the curtain on one of its key tests. read more By Ben Adams After kick-starting its first-in-human test back in March, Bolt Therapeutics has nabbed a meaty $93.5 million round to help fund its clinical work. read more By Ben Adams With stints at the likes of Genzyme, Bayer and, most recently, TranScrip Partners, Gilbert Wagener, M.D., Ph.D., is now signing up to U.K. biotech Rexgenero. read more By Ben Adams Annexon has grabbed a healthy $100 million round to take its clinical work closer to the finishing line as it tees up shots on multiple targets. read more By Arlene Weintraub Antivirals from Roche, Bristol Myers Squibb, Viiv and Gilead, or modified versions of them, could prove effective against COVID-19, reported researchers from Columbia University and the University of Wisconsin-Madison. What's key is their ability to disrupt a protein called polymerase. read more By Angus Liu GlaxoSmithKline and Akebia have won global first nods for their novel anemia drugs in Japan. Novartis has ditched an application for its Takeda-bought eye med Xiidra in Europe. Takeda is treading deeper into gene therapy with a deal potentially worth $900 million with Carmine Therapeutics. And more. read more By Kyle Blankenship Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director. read more Resources Sponsored by: PRA Health Sciences Collaboration across the industry will be key to meeting the demands of the RACE Act and ensuring pediatric patients receive the care and treatments they need. Sponsored by: Systech Get an inside look… Merck shares its next-generation approach to supply chain protection with new digital platforms, including Blockchain. Sponsored by: Automation Anywhere Built on advances in Artificial Intelligence (AI), data mining, and information integration into various systems at 100% accuracy, the new era of intelligent automation is integral to life sciences for devising new treatments faster and at a lower expense. Sponsored by: Research Solutions Learn four ways to squeeze more value from your limited R&D resources. Sponsored by: BioAnalytix Download this eBook and Learn the Advanced Analytical Approaches for Improved Development of Cell and Gene Therapies Sponsored by: Blue Matter, strategic consultants in the life sciences White paper describing 7 keys to success for any biopharma company that is entering (or thinking about entering) Europe. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 